A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer

BACKGROUND: Targeted therapies in HER2-positive metastatic breast cancer significantly improve outcomes but efficacy is limited by therapeutic resistance. HER2 is an acutely sensitive Heat Shock Protein 90 (HSP90) client and HSP90 inhibition can overcome trastuzumab resistance. Preclinical data sugg...

Descripción completa

Detalles Bibliográficos
Autores principales: Jhaveri, Komal, Wang, Rui, Teplinsky, Eleonora, Chandarlapaty, Sarat, Solit, David, Cadoo, Karen, Speyer, James, D’Andrea, Gabriella, Adams, Sylvia, Patil, Sujata, Haque, Sofia, O’Neill, Tara, Friedman, Kent, Esteva, Francisco J., Hudis, Clifford, Modi, Shanu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540198/
https://www.ncbi.nlm.nih.gov/pubmed/28764748
http://dx.doi.org/10.1186/s13058-017-0879-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540198/
https://www.ncbi.nlm.nih.gov/pubmed/28764748
http://dx.doi.org/10.1186/s13058-017-0879-5

Ejemplares similares